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A yellow fever–Zika chimeric virus vaccine candidate protects
against Zika infection and congenital malformations in mice
Dieudonné B. Kum1, Niraj Mishra1, Robbert Boudewijns1, Ivan Gladwyn-Ng2, Christian Alfano2, Ji Ma1, Michael A. Schmid1,
Rafael E. Marques 3, Dominique Schols1, Suzanne Kaptein1, Laurent Nguyen2, Johan Neyts1 and Kai Dallmeier1
The recent Zika virus (ZIKV) epidemic in the Americas led to an intense search for therapeutics and vaccines. Here we report the
engineering of a chimeric virus vaccine candidate (YF-ZIKprM/E) by replacing the antigenic surface glycoproteins and the capsid
anchor of YFV-17D with those of a prototypic Asian lineage ZIKV isolate. By intracellular passaging, a variant with adaptive
mutations in the E protein was obtained. Unlike YFV-17D, YF-ZIKprM/E replicates poorly in mosquito cells. Also, YF-ZIKprM/E does
not cause disease nor mortality in interferon α/β, and γ receptor KO AG129 mice nor following intracranial inoculation of BALB/c
pups. A single dose as low as 1 × 102 PFU results, as early as 7 days post vaccination, in seroconversion to neutralizing antibodies
and confers full protection in AG129 mice against stringent challenge with a lethal inoculum (105 LD50) of either homologous or
heterologous ZIKV strains. Induction of multi-functional CD4+ and CD8+ T cell responses against ZIKV structural and YFV-17D non-
structural proteins indicates that cellular immunity may also contribute to protection. Vaccine immunogenicity and protection was
confirmed in other mouse strains, including after temporal blockade of interferon-receptors in wild-type mice to facilitate ZIKV
replication. Vaccination of wild-type NMRI dams with YF-ZIKprM/E results in complete protection of foetuses against brain
infections and malformations following a stringent intraplacental challenge with an epidemic ZIKV strain. The particular
characteristic of YF-ZIKprM/E in terms of efficacy and its marked attenuation in mice warrants further exploration as a vaccine
candidate.
npj Vaccines            (2018) 3:56 ; https://doi.org/10.1038/s41541-018-0092-2
INTRODUCTION
The recent outbreak of the ZIKV in the Americas1 affected over 80
countries. The World Health Organization (WHO) declared the
epidemic a global health emergency in particular because of the
high rates of ZIKV-induced congenital malformations. The ZIKV is a
flavivirus; several other medically important pathogens such as
the dengue (DENV), the Japanese encephalitis (JEV), the tick-borne
encephalitis (TBEV), the West Nile (WNV), and the yellow fever
viruses also belong to this genus. The live-attenuated yellow fever
virus, YFV-17D vaccine, developed by Max Theiler in 19372 is a
paradigm of an efficient and safe flavivirus vaccine. Vaccination
with YFV-17D results in a rapid induction of (life) long-lasting
protective immunity against YFV following a single dose of the
vaccine. Since its discovery, the vaccine has been administered to
an estimated 600 million people worldwide3 and is, based on its
legacy track record, generally considered safe with only rare (~1
per million) serious adverse side effects [i.e., in particular vaccine-
associated viscerotropic disease] limited primarily to specific risk
groups.4 Several YFV-17D-based chimeric vaccines against the
JEV5,6 (Imojev®), the DENV7 (Dengvaxia®), and the WNV8
(ChimeriVax-WN02) have been constructed wherein the prM/E
genes of YFV-17D are replaced with each of the corresponding
genes of the stated viruses.
Flaviviruses have a positive-sense single-strand RNA genome of
~11,000 nucleotides, which contains a 5′-untranslated region
(UTR), a long open reading frame (ORF) and a 3′ UTR. The ORF
encodes a single polyprotein precursor that comprises three
structural (capsid [C], precursor membrane [prM], and envelope
[E]) and seven non-structural (NS1–5) proteins. The structural
proteins form, together with the viral RNA, the infectious viral
particles whereas the NS proteins mediate viral replication but are
for example also involved in the evasion and modulation of
immune responses in infected cells.9 The signal peptide at the C
terminus of the C protein (C anchor domain, Canch) regulates
flavivirus packaging through coordination of sequential cleavages
at the N terminus (by the viral NS2B/NS3 protease) and C terminus
(by host signalases in the endoplasmic reticulum [ER] lumen) of
the signal peptide sequence.10,11 Mutational studies demonstrate
the importance of the signal sequence in viral particle formation
and thus replication.12,13 Likewise, the assembly of viral particles
can be markedly impaired when the prM/E genes of a particular
flavivirus are exchanged in frame with the C-signal peptide of
another flavivirus (Supplementary Fig 1). Whether a chimeric
construct should contain the signal sequence of either the
parental or the inserted virus is unpredictable, since efficient
processing of the polyprotein and viral fitness do not necessarily
correlate.12,14,15
Received: 19 March 2018 Accepted: 5 November 2018
1KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium; 2GIGA-Neurosciences, Interdisciplinary
Cluster for Applied Genoproteomics (GIGA-R), University of Liège, C.H.U. Sart Tilman, Liège, Belgium and 3Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for
Research in Energy and Materials (CNPEM), Campinas, Sao Paulo, Brazil
Correspondence: Johan Neyts (johan.neyts@kuleuven.be) or Kai Dallmeier (kai.dallmeier@kuleuven.be)
These authors contributed equally: Niraj Mishra, Robbert Boudewijns.
www.nature.com/npjvaccines
Published in partnership with the Sealy Center for Vaccine Development
While chimeric constructs based on the backbone of a non-
attenuated DENV-2 strain D2Y98P or virulent ZIKV Cambodian
strain FSS13025 have been generated,16 it is generally believed
that the determinants of attenuation are largely associated with
the backbone of the construct.17 Considering both, the high safety
profile of YFV-17D17 and the neurovirulent properties of ZIKV18
from recent epidemics, we engineered (employing our proprietary
DNA-YFV-17D plasmid, WO2014174078A1, Supplementary Fig 2a)
a chimeric YF-ZIKprM/E construct (Fig. 1a) by swapping the
sequence that encodes for the antigenic surface glycoproteins of
YFV-17D with that of a prototypic Asian lineage ZIKV strain
(isolated from the Yap Island in 2007). This pre-epidemic ZIKV
strain does not carry the serine-to-asparagine (S139N) mutation in
prM that has been found dominating in ZIKV outbreaks after
2013.19 Strains with this S139N mutation have been associated
with increased ZIKV infectivity for both human and mouse
neuronal progenitor cells and have been linked to neurovirulence
(microcephaly) and mortality in foetuses.18 The chimeric virus
consists of the antigenic determinants (prM and E) plus the capsid
anchor sequence of ZIKV and the replication machinery (NS1–5),
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Construction and rescue of chimeric YF-ZIKprM/E
Following transfection of Vero E6 with the YF-ZIKprM/E construct
(Fig. 1b) or a mCherry-tagged reporter virus variant thereof
(Supplementary Fig 2a), replication of the chimeric virus appeared
to be restricted to (some of) the transfected cells (Fig. 1b and
Supplementary Fig 2b, c). However, no spread to neighboring cells
was noted nor was virus released in the culture supernatant [as
demonstrated by lack of detectable virus RNA by RT-PCR (limit of
detection ~100 viral RNA copies/ml)] of cell culture supernatants
harvested daily after transfection. This chimeric virus appeared to
be replication-deficient with an apparent block prior to virus
release. We hence explored strategies to propagate this virus
(Supplementary Fig. 3). Firstly, classical approaches of either (a)
serial passaging of culture supernatants of transfected cells in
tissue culture or (b) intracranial inoculation and passaging in the
brain of mice failed to yield measurable virus progeny neither by
virus isolation, nor by causing any measurable signs of disease.
Here we also explored various modifications to the chimeric YF-
ZIKprM/E construct (variants) so that the virus carried the capsid
anchor (C-signal sequence) of either YFV-17D or that of ZIKV
(Supplementary Fig. 1). However, supernatant of cells transfected
with either constructs did not cause any morbidity such as
behavioral changes or weight loss in highly susceptible AG129
mice,20,21 neither following intracranial inoculation of 6-weeks-old
mice (Supplementary Fig. 2d). In a further attempt to overcome
the abortive infection, we explored whether subculturing of cells
transfected with the cDNA construct would ultimately result in
spread of the chimeric virus. Remarkably, following already one
passage of subculturing of the transfected cells, foci of infected
cells were observed 7 days post transfection (Fig. 1b). Continued
subculturing for in total four passages (Supplementary Table 1) of
the infected/transfected cultures resulted in a further spread of
replicating virus (Fig. 1b, intracellular passage 1–2 and extra-
cellular passage 1). The chimeric nature of the construct was
confirmed by Sanger sequencing and by differential staining for
the different antigens using YFV and ZIKV-specific monoclonal
antibodies (Fig. 1c). Emergence of detectable amounts of chimeric
virus in the culture supernatant, finally allowed further propaga-
tion of the virus to relatively high titers (approximately 1 × 107
genomic copies/ml) in Vero E6 cells (Fig. 1d). The resulting virus
had acquired two mutations in the E gene leading to a serine-to-
leucine (S455L) and an alanine-to-threonine (A40T) change in the
E protein [amino acid positions according to Theys et al.22].
(Supplementary Fig. 5 and Supplementary Table 2). Reverse
engineering of these tissue culture adapted (TCA) mutations into
the non-adapted virus (NAV) (Supplementary Fig. 6a) or the
mCherry-tagged variant thereof resulted in the rescue of the
otherwise replication incompetent chimeric virus to full infectivity
(Supplementary Fig. 6b).
Attenuation of chimeric YF-ZIKprM/E
Insufficient attenuation poses a safety risk for live vaccines.
Therefore YF-ZIKprM/E was compared to the licensed YFV-17D. A
reduced plaque size phenotype of a virus typically serves as a
proxy for attenuation. The plaques formed by YF-ZIKprM/E virus
on BHK-21J cells were smaller than those formed by YFV-17D and
were comparable in size to those formed by the safe chimeric
ChimeriVax-JE (Fig. 1e). YFV-17D replicates poorly in C6/36
mosquito cells (i.e. less efficiently than in mammalian cells) in
contrast to wild-type YFV.23 Intriguingly, YF-ZIKprM/E, in contrast
to YFV-17D, did not result in measurable amplification in C6/36
cells (Fig. 1f). This suggests that vector-borne transmission of this
new live-attenuated vaccine candidate can be considered unlikely
(as is also the case for YFV-17D). Next, when AG129 mice20 were
inoculated intraperitoneally (i.p.) with a high dose of 1 × 106 PFU
of YF-ZIKprM/E, no observable signs of disease such as behavioral
changes (hunched posture, ruffled fur, agitation/lethargy) or CNS
involvements (such as paralysis) was noted during a 28 day follow-
up period. However, when mice were injected with a much lower
inoculum (1 × 103 PFU or 104-fold lower) of the parental YFV-17D,
a rapid and consistent induction of disease necessitating
euthanasia was observed (Supplementary Fig. 2E). Intracranial
inoculation of 5-days-old BALB/c mouse pups with 1 × 104 PFU of
YF-ZIKprM/E did not result in any signs of diseases or mortality.
This is in stark contrast to YFV-17D since intracranial inoculation of
pups with as little as 10 PFU of this virus results in marked growth
retardation (Supplementary Fig. 8a, b) and severe disease
requiring euthanasia (mean day to euthanasia, MDE 9 ± 1days).
YF-ZIKprM/E is thus at least 106-fold attenuated over YFV-17D in
adult AG129 mice and at least 103-fold following intracranial
inoculation in BALB/c pups. Although BALB/c pups intracranially
inoculated with YF-ZIKprM/E did not show any signs of disease,
replication of the virus in the brain was confirmed by means of
qRT-PCR (Supplementary Fig. 8c). Interestingly, no emergence of
variants that carry the neurovirulent prM S139N mutation18 was
noted in the brains of these mice (Supplementary Fig. 8d).
Immunogenicity and efficacy of YF-ZIKprM/E against lethal
challenge in a stringent AG129 mouse model
To demonstrate the immunogenicity and efficacy of YF-ZIKprM/E,
adult AG129 mice were used; these are known to be highly
susceptible following peripheral inoculation with minute amounts
of ZIKV (10 PFU and less21). Mice were vaccinated i.p. with 1 × 104
PFU of YF-ZIKprM/E or sham (MEM medium containing 2% FBS,
the same medium used to prepare virus stock). In line with
anticipated vaccine safety, all vaccinated mice remained healthy
without weight loss. On day 21, blood was collected after which
mice were challenged via the i.p. route with 1 × 104 PFU
(corresponding to ~104 LD50) of the ZIKV strain MR766.
21 In total
Fig. 1 Construction and propagation of YF-ZIKprM/E. a Schematic representation of the YF-ZIKprM/E construction: ZIK-5′A contains the
capsid anchor (C anch) sequence of YFV-17D whereas ZIK-5′B contains the C-signal sequence of ZIKV. ZIKV Yap (2007) sequence nt 313 to 2382
was cloned into YFV-17D between nucleotides 422 and 2451. b Immunofluorescence assay at selected time points after transfection of Vero
E6 cells with YF-ZIKprM/E plasmid. At 2, 8, and 14 days post transfection (dpt), cultures were split and transferred to larger flasks and further
cultured (Supplementary Table 1). After each split, a part of the cells was seeded in 8-well chamber slides and stained for viral antigen using
pan-flavivirus monoclonal antibody (mAb) 4G2 (at 1, 3, and 5, days post split [dps]). Upper panels represent intracellular passages 1 and 2,
respectively. Supernatant of passage 4 was used to infect naïve Vero E6 cells and virus infection and spread was monitored at indicated time
points (bottom panel). c Antigenicity of YF-ZIKprM/E: Vero E6 cells were infected with either YFV-17D, ZIKV BeH819015,45 or YF-ZIKprM/E at
multiplicity of infection (MOI) of 0.1 and stained 2dpi with pan-flavivirus antibody 4G2, anti-YFV NS1 mAb 1A5 or JEV E-specific mAb MA1-
71256 that shows strong cross-reactivity only with ZIKV and YF-ZIKprM/E, but not with the YFV E protein. d Extracellular passaging of YF-
ZIKprM/E in Vero E6 cells and quantification of viral RNA. Arrows indicate the first detection of ZIKV E protein mutations S455L and A40T,
respectively. e YF-ZIKprM/E chimeric virus (Passage 5) forms smaller plaques (developed and stained 7dpi; complete well of a 6-well plate
shown: diameter = 34.8 mm) on BHK-21J cells than the parental YFV-17D, similar to those formed by ChimeriVax-JE. f Replication kinetics of
YFV-17D (red circles) and YF-ZIKprM/E (blue squares) on mammalian (Vero E6) and mosquito (C6/36) cell lines. Cells were infected with YFV-
17D and YF-ZIKprM/E (Passage 5) at MOI of 0.01 and extracellular progeny viral RNA was quantified over time by qRT-PCR. Data are presented
as mean values with error bars indicating SEM of n= 2 replicates. Dotted line denotes the limit of detection (L.O.D) of the qRT-PCR assay
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n= 15 mice (three independent experiments) were vaccinated of
which all but one (95%) seroconverted to virus neutralizing
antibodies (nAb) with PRNT50 titers between 1:60 and 1:1235
[log10 geometric mean titer (GMT) 2.4] (Fig. 2a). Animals were
monitored daily for weight loss and visible signs of disease. Five
successfully immunized animals were challenged with 1 × 104 PFU
of ZIKV MR766; these mice were fully protected from virus-
induced weight loss and mortality (Fig. 2b, e), whereas all sham-
vaccinated mice (n= 5) developed ZIKV-induced disease and had
to be euthanized (MDE 14 ± 1). The efficacy of the vaccine
construct in protecting against challenge viremia and virus
dissemination was assessed in a subset of vaccinated mice.
Therefore vaccinated and sham-vaccinated mice (n= 10 each; two
independent experiments) were euthanized 5 and 14 days post
ZIKV MR766 challenge, respectively, and viral RNA load in different
organs was quantified by means of qRT-PCR. Both at day 5 (peak
viremia in sham-vaccinated mice) and 14 post challenge (at MDE
in sham-vaccinated mice), viral RNA was undetectable in at least 8
out of 10 vaccinated mice (Fig. 2c). At day 14, the single mouse
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Fig. 2 In vivo immunogenicity of YF-ZIKprM/E and protection of AG129 mice against lethal challenge with ZIKV MR766. a Seroconversion of
vaccinated mice: AG129 mice (n= 15) were inoculated with 1 × 104 PFU of YF-ZIKprM/E and the titers of ZIKV-specific neutralizing antibodies
were assessed in serum at 21 days post immunization by PRNT (blue squares). Data compiled from three independent experiments with n= 5
per group. Sera from sham-vaccinated (n= 10) as controls (red circles). b ZIKV MR766 challenge: Twenty-one days post vaccination, vaccinated
(blue squares, n= 5) and sham-vaccinated (red circles, n= 5) mice were challenged with 1 × 104 PFU of ZIKV MR766. Vaccinated mice were
monitored for 28 days, and remained healthy until the end of the experiment. Protection from ZIKV viremia c and virus dissemination to target
organs d, e after challenge of vaccinated (blue squares, n= 10) and sham-vaccinated (red circles, n= 10) AG129 mice. Blood and organs were
collected at day 5 d and 14 e post challenge. The subset of mice represented in c–e were not included in the survival analysis b because
animals needed to be sacrificed earlier for organ collection. However, at euthanasia day 14 post challenge all sham-vaccinated mice showed
signs of severe ZIKV-induced disease, as well as that particular YF-ZIKprM/E vaccinated animal that failed to seroconvert prior to challenge a
resulting in viral break-through (outliers in c and e). Data are presented as mean values with error bars indicating SEM from two independent
experiments (n= 5 each). Mann–Whitney two-tailed test was used for all statistical calculations. P values < 0.05 were considered statistically
significant. *P < 0.05, **P < 0.01, ***P < 0.001. Horizontal dotted lines denote the limit of detection (L.O.D) of the assay
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prior to challenge [and that may have likely not been properly
injected/vaccinated] had high viral RNA loads (Fig. 2c). Overall,
there was an almost 4log10 reduction in serum viral load in
vaccinated mice (Fig. 2c). Vaccination resulted also in complete
reduction of viral loads in different organs including brain and
testes at day 5 (Fig. 2d) and 14 (Fig. 2e) post challenge.
Vaccine efficacy against lethal infection was also demonstrated
when mice were challenged with the more aggressive South
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American (Suriname) ZIKV SL1602 isolate24 (Fig. 3a, b) following i.
p. infection with either low (1 × 103 PFU) or high (1 × 105 PFU)
titers of the virus (Supplementary Fig. 9a, b). This was
corroborated by undetectable viral RNA (Fig. 3c) and infectious
virus (Supplementary Fig. 9c) at peak viremia 3 days post
challenge, even in mice vaccinated with a vaccine dose as low
as 1 × 102 PFU (Fig. 3d; for similar results using ZIKV MR766 see
Supplementary Fig. 10a, b). Vaccinated mice did not show any
challenge virus-induced elevation of serum cytokines (Fig. 3E) as
demonstrated for IFN-γ, IL-18, IL-6, MCP-1, and others (Supple-
mentary Table 3) that have previously been shown to be a
sensitive marker of ZIKV replication and disease progression in the
AG129 mouse model.21 Vaccination with YF-ZIKprM/E resulted
already after 7 days in high titers of ZIKV-specific antibodies, the
plateau phase was reached by day 10 (Supplementary Fig. 10c). All
vaccinated mice (except 1 from the 21 day vaccination group
which failed to seroconvert) were protected from an otherwise
lethal challenge with 1 × 104 PFU of a heterologous ZIKV
MR766 strain (Supplementary Fig. 10d).
To assess the specificity of the cellular immune responses and
to seek some evidence for longevity of the immunity, the
magnitude of (memory) T cell responses elicited by YF-ZIKprM/E
was studied several months after vaccination. ZIKV structural
proteins are major targets of both CD4+ and CD8+ T cell
responses.25 In the case of YFV-17D, structural as well as non-
structural proteins have been shown to be involved in vigorous,
broad and polyfunctional T cell responses both in mice and
humans.26 AG129 mice were vaccinated with 1 × 104 PFU of YF-
ZIKprM/E and splenocytes were harvested 10 weeks after
vaccination. YFV-17D and ZIKV-specific memory T cell responses
were assessed by ELISPOT (Fig. 4a, b) as well as by intracellular
cytokine staining (Fig. 4c–f). To that end splenocytes were
incubated overnight with peptides derived from ZIKV E or with
total ZIKV antigen (ZIKV-infected cell lysate) as recall antigens. This
stimulation resulted in clear ZIKV-specific cellular responses, as is
evident for the IFN-γ ELISPOT by a median (n= 5) increase (over
background) of 1770 and 133 spots/106 cells, respectively (Fig. 4a,
b). Antigen-specific cytokine production was further assessed by
the analysis of intracellular IFN-γ and TNF-α levels by means of
flow cytometry (Fig. 4c–f). Results indicate that multi-functional
CD8+ and CD4+ T cell responses with a cytotoxic Th1 polarization
(Supplementary Fig. 11) may, in the case of YF-ZIKprM/E,
contribute to protection against ZIKV challenge after vaccination.
Of note, cellular responses were skewed towards the YFV-17D
backbone (Fig. 4d, f and Supplementary Fig 11) but still showed a
marked recall for ZIKV antigens, which is in contrast to the YFV-
17D-based Dengvaxia® vaccine that has been reported not to
result in pronounced DENV specific T cell immunity.27 Never-
theless, such results obtained in animal models, in particular in
immunocompromised AG129 mice, should be interpreted with
caution and may not per se allow to predict human cellular
immune responses.
Comparative potency of YF-ZIKprM/E in other mouse models
The seek further evidence for the efficacy of the construct and to
exclude that the observations made in AG129 mice may have
been largely biased by particular characteristics of these mice, we
next assessed the effect of YF-ZIKprM/E in (i) immunocompetent
wild-type BALB/c and C57BL/6 mice as well as in (ii) mice that are
solely deficient in the interferon α/β receptor (ifnar−/−) (Fig. 5a, b).
In brief, 4–6-weeks-old mice were either vaccinated with 1 × 104
PFU YF-ZIKprM/E or were sham-vaccinated. For the ease of
quantification, an indirect immunofluorescence assay (IIFA) was
used as surrogate for PRNT to quantify ZIKV-specific Abs [IIFA end
point titers correlated strongly with PRNT50 values (Supplementary
Fig. 10e, f)]. All YF-ZIKprM/E vaccinated mice seroconverted to
ZIKV-specific Abs with titers that were highly dependent on the
mouse strain used (Fig. 5a). Vaccination of ifnar−/− mice result
rapidly in the induction of very high titers of antibodies that cause
sterilizing immunity (no increase in ZIKV-specific Abs after
challenge), and full protection against challenge viremia (Fig. 5a,
b). Vaccination of immunocompetent C57BL/6 mice resulted in
much lower titers of ZIKV-specific antibodies, but resulted in full
protection against viremia as well (Fig. 5a, b). By contrast, although
vaccination of BALB/c mice resulted in antibody titers that were
comparable to those observed in C57BL/6 mice, there was little if
any effect on challenge viremia in these mice (Fig. 5a, b).
Generally, vaccine potency correlates directly with the extent with
which the live-attenuated viruses replicate after inoculation.
Therefore, the interferon receptor (IFNAR) blocking antibody
MAR1-A53 was injected in an attempt to render C57BL/6 and in
particular BALB/c mice more susceptible to YF-ZIKprM/E replica-
tion (and thus increase its immunogenicity). Pre-treatment of mice
with MAR1-A53 before vaccination resulted in a significant
increase in Ab titers in C57BL/6 mice, but not in BALB/c mice
(Fig. 5a, b). Under this condition, sterilizing immunity was
obtained in C57BL/6 mice, which was evident from the fact that
there was no further increase in Ab titers after challenge. In MAR1-
A53 pre-treated BALB/c mice, ZIKV Ab titers still raised significantly
following challenge infection. A slight reduction in challenge
viremia was however noted, and in some of the mice, no viremia
was anymore detectable.
Protection by YF-ZIKprM/E from ZIKV-induced congenital
malformations
It was next studied whether YF-ZIKprM/E protects against vertical
transmission of the virus in a stringent intra-placental ZIKV
Fig. 3 Protection of vaccinated AG129 mice against lethal challenge with ZIKV strain SL1602. AG129 mice were vaccinated (blue squares, n=
10) with 1 × 104 PFU of YF-ZIKprM/E or sham-vaccinated (red circles, n= 10). Weight a and time to euthanasia b were monitored after
challenge with either 1 × 103 PFU or 1 × 105 PFU of ZIKV SL1602. All vaccinated mice were grouped irrespective of the challenge dose. See
Supplementary Fig. 9c and d for details about individual groups. c Protection from viremia in vaccinated AG129 mice: AG129 mice that had
either been vaccinated with 1 × 104 PFU of YF-ZIKprM/E (blue squares, n= 10) or that were sham-vaccinated (red circles, n= 10) were
challenged with 1 × 105 PFU or 1 × 103 PFU of ZIKV SL1602 and viral RNA copy numbers were assessed at 3 days post challenge. All vaccinated
mice were grouped irrespective of the challenge dose. See Supplementary Fig. 9c and d for details about individual groups. Sera from
vaccinated mice collected pre-challenge served as controls. d AG129 mice were vaccinated with either 1 × 102 PFU, 1 × 104 PFU or 1 × 106 PFU
of YF-ZIKprM/E (blue squares, n= 5 per group) and were challenged with 1 × 105 PFU of ZIKV SL1602 and ZIKV RNA copies in serum on day 3
post challenge were measured. Because of increased background values of qRT-PCR due to change in virus strain (MR766 to SL1602), values
are reported as fold changed in RNA copies compared to serum RNA values of vaccinated mice prior to challenge. e Expression of cytokines
3 days post challenge: Vaccinated (closed squares, n= 5) and sham-vaccinated (closed circles, n= 5) mice were challenged with 1 × 105 PFU of
ZIKV SL1602 and levels of IFN-γ, IL-18, IL-6, MCP-1, and other cytokines (Supplementary Table 3) were assessed 3 days post challenge. Data are
presented as mean values with error bars indicating SEM. Mann–Whitney two-tailed test was used for statistical analyses. Asterisk indicates a
significant difference *P-values < 0.05, **P-values < 0.01. Background (dotted line) represents average RNA copies of vaccinated mice before
challenge or the limit of detection (L.O.D) of the assay
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challenge mouse model.28 Female wild-type NMRI mice were
vaccinated, two weeks before mating, in the presence of MAR1-
A53 Ab with either a single dose (1 × 104 PFU of YF-ZIKprM/E) or
with sham (Fig. 6a). Serum levels for ZIKV-specific Abs achieved in
vaccinated dams at 21dpv (i.e. 5 days prior to challenge) (Fig. 6b)
were comparable to the titers measured in C57BL/6 mice (Fig. 5a).
Twelve days after conception (embryonic age E12.5), the
developing embryos (16–22 per group) were challenged intra-
placentally (IPL) with 1 × 105 TCID50 of ZIKV strain (French
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(E18.5) foetuses were analyzed. Pups from vaccinated mothers had
undetectable levels (by qRT-PCR) of ZIKV RNA (>4log10 reduction;
n= 16 sham-vaccinated/challenged; n= 22 vaccinated/chal-
lenged; p < 0.001) similar to non-challenged pups (n= 17 sham-
vaccinated/mock-infected; n= 16 vaccinated/mock-infected). Acti-
vation of apoptotic caspase-3 (ACC3, Fig. 6d), and as consequence
a general disorganization of the cortical layers and thinner upper
layers, was only and consistently observed in ZIKV antigen positive
brains of pups from sham-vaccinated dams following IPL
challenge. Thus, vaccination with a single dose (1 × 104 PFU) of
YF-ZIKprM/E prior to pregnancy, conferred full protection against
fetal infection and associated malformations, even when chal-
lenged by direct IPL inoculation thereby bypassing the feto-
maternal barrier.
DISCUSSION
A number of ZIKV vaccine candidates have been developed
employing various approaches and technologies,29 ranging from
subunit DNA/RNA vaccines,30,31 virus-like particles32,33 and inacti-
vated whole virus,34 over virus vectored35 to live-attenuated
virus36, and chimeric virus37 vaccines. Several proved efficient in
protecting against experimental challenge in mice and some also
in non-human primates. Only a few candidates have been shown
to be efficacious against vaccine challenge in very stringent
interferon-α/β and γ-receptor-deficient (IFNAGR-KO) mouse mod-
els [AG129:32–34 AGB6:38], as well as in murine ZIKV pregnancy
challenge models.37,39 To our knowledge, the vigorous intra-
placental ZIKV challenge model28 has not been used before to
assess protection from ZIKV-induced congenital malformations.
We generated a chimeric live-attenuated ZIKV vaccine candi-
date (YF-ZIKprM/E) by swapping the capsid anchor (Canch) and
prM/E sequence of the YFV-17D vaccine virus with that of the
corresponding sequence of a pre-epidemic Asian ZIKV strain. The
ZIKV isolate that was used to this end carries a serine at position
17 in the ZIKV prM (position 139 in the ZIKV polyprotein)22, rather
than the asparagine that has been reported to be associated with
microcephaly. In contrast to other YFV-17D-based chimeric
constructs,5,40 where the Canch sequence of the backbone virus
was required for infectivity, we found that the Canch of ZIKV was
needed here. In addition, the chimeric virus required adaptive
mutations for efficient replication and extracellular release.
Already during construction of the original chimeric cDNA
construct, two presumably replication-enhancing mutations were
adopted from the modified YFV-17D backbone of ChimeriVax-JE6
(Supplementary Fig. 4 and Supplementary Table 2). Another two
mutations were consecutively acquired after intracellular passage
of the virus. The two adaptive mutations (G1097A resulting in
A40T and C2343T resulting in S455L) in the E gene22 were shown,
by reverse engineering, to be sufficient and required for increased
infectivity and propagation of the vaccine virus to higher titers
(Supplementary Fig. 6). These mutations likely contribute to
unlocking a block of the chimeric YF-ZIKprM/E at the level of virus
release. S455L is located immediately upstream of the transmem-
brane anchor domains (TM) 1 and 2 of the E protein. TM1 and TM2
are involved in regulation of flaviviral particle maturation41 and
function as endoplasmic reticulum retention signal.42 A threonine
is commonly found at position 40 in current ZIKV strains; this T40
residue is located at the surface of the E protein, but is not
involved in Ab mediated neutralization.43 Nevertheless, the two
amino acid changes were found to also enhance the infectivity of
YF-ZIKprM/E in a panel of human cell types that are known to
support ZIKV replication (Supplementary Fig. 7). YF-ZIKprM/E has a
smaller plaque phenotype than YFV-17D, and unlike the parental
virus, replicates poorly in mosquito cells. Remarkably, and again in
sharp contrast to YFV-17D, YF-ZIKprM/E does not cause disease
when inoculated intracranially (even at very high titers) in BALB/c
pups or systemically in adult (IFNAGR-KO) AG129 mice. The
remarkable attenuation of YF-ZIKprM/E may be a beneficial
characteristic when further development as a vaccine is envi-
saged. Poor replication in mosquito cells may be an additional
asset [although there is no evidence that the parent YFV-17D
(which replicates in mosquito cells) can be transmitted by
mosquitos].
We first assessed the effect of the YF-ZIKprM/E in a stringent
ZIKV infection model in AG129 mice. Even a minute inoculum of
the ZIKV (and of most other flaviviruses), results rapidly in disease
and mortality in these mice.21 Vaccination of AG129 mice with YF-
ZIKprM/E results in rapid seroconversion (within 7 days) to high
levels of virus neutralizing antibodies. These mice are protected
against ZIKV viremia and virus-induced disease both following
homologous and heterologous challenge. Overall, sterilizing
immunity was obtained in most animals, with a ~4log10 reduction
in serum viral load and no detectable viral RNA in various organs
(including brain and testes). Even an inoculum as low as 102 PFU
of YF-ZIKprM/E proved sufficient to result in protective immunity.
For YFV-17D, both in mice and in humans, structural as well as
non-structural proteins have been shown to be involved in
vigorous, broad and polyfunctional T cell responses26. We
observed clear ZIKV-specific cellular responses that are multi-
functional (CD8+ and CD4+ T cell responses with a cytotoxic Th1
polarization) in nature. Even though cellular responses were
skewed towards the YFV-17D backbone, a marked recall for ZIKV
antigens was noted. This is in contrast to the observations made
for Dengvaxia® vaccine27.
To exclude that the observations made in the interferon
receptor KO AG129 mice are the results of an aberrant mouse
strain/immune system, we assessed the effect of YF-ZIKprM/E in
immune competent mice (C57BL/6, BALB/c and NMRI) as well as in
interferon α/β receptor (ifnar−/−) KO mice. Vaccination with YFV-
ZIKprM/E resulted in consistent potency in wild-type C57BL/6 mice
and in NMRI mice (for the latter see infra) Only in BALB/c mice, the
chimeric vaccine largely failed to induce protective immunity.
When the interferon receptors were blocked pharmacologically
(using an antibody) in BALB/c mice, at least some of the mice
(70%) had undetectable levels of viremia after challenge. When
Fig. 4 Analysis of cellular immunity (CD4+ and CD8+ T cells and cytokine response profiles) in vaccinated and sham-vaccinated AG129 mice.
AG129 mice were vaccinated (n= 5, from two independent experiments) i.p. with 1 × 104 PFU of YF-ZIKVprM/E. Ten weeks post vaccination,
memory T cells were probed for either YFV-17D or ZIKV-specific recall responses in an ELISPOT. a Representative IFN-γ ELISPOT wells after
overnight stimulation of 4 × 105 splenocytes with the indicated antigen (complete well of a 96-well plate shown: diameter = 6.4 mm). b Spots
per million splenocytes in IFN-γ ELISPOT after overnight stimulation with the indicated antigen. For each mouse, values are normalized by
subtracting the number of spots in control wells (stimulated with Vero E6 cell lysate only). Median values are indicated with bars. c Intracellular
cytokine expression levels of memory T cells in the spleen were analyzed 10 weeks after vaccination of 6–8-weeks-old male AG129 mice (n=
5, from two independent experiments) with 1 × 104 PFU of YF-ZIKVprM/E. CD4+ T cells are defined as Zombie Aqua− (ZA−), CD3+, and CD8−. d
Representative TNF-α and IFN-γ expression profiles of CD4+ T cells following overnight stimulation with the indicated antigen. Numbers
represent percentages of positive cells of the total CD4+ T cell population for each quadrant. e Intracellular cytokine expression levels of
memory T cells. CD8+ T cells are defined as ZA−, CD3+, and CD8+. f Percentages of TNF-α-positive and IFN-γ-positive CD8+ T cells, normalized
by subtracting the percentage of positive cells in corresponding control samples (stimulated with Vero E6 cell lysate). Data are presented as
mean values with error bars indicating SEM. Background (dotted line) represents average values for sham-vaccinated mice
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immunocompetent NMRI mice dams were vaccinated with YFV-
ZIKprM/E (in the presence of the interferon receptor blocking
antibody) their fetuses were completely protected against a
stringent intra-placental challenge with the ZIKV (at day 12 after
conception; embryonic age E12.5). No viral RNA was detectable
nor were any malformations observed. In three other studies in
which the effect of vaccination of murine dams [with, respectively,
two live-attenuated38,39 and one chimeric ZIKV vaccine37] on their
foetuses was studied, either a non-sterilizing reduction in viral
loads in the embryo heads was observed39 or was not
reported.37,38 All three vaccine candidates prevented however
congenital malformations. It should be noted that the model of
direct intra-placental inoculation as used in the present study, is
likely more vigorous than the peripheral challenge models used
before;37,39 yet YFV-ZIKprM/E was able to completely prevent
infection in the foetuses.
In conclusion, we generated a chimeric live-attenuated ZIKV
vaccine candidate (YFV-ZIKprM/E) by swapping the Canch and
prM/E sequences of a pre-epidemic Asian ZIKV into the YFV-17D
backbone (that carried itself two mutations from the Imojev®
construct). The resulting virus was initially over-attenuated, but
acquisition of two tissue culture adaptive (TCA) mutations allowed
to amplify the chimeric virus to high titers. This virus is, in stark
contrast to the parent virus YFV-17D, avirulent in AG129 mice as
well as following intracranial inoculation in mouse pups. In
contrast to YFV-17D, YFV-ZIKprM/E replicates poorly in mosquito
cells. The virus is highly effective in inducing a protective immune
response in various mouse models (including immunocompetent
C57BL/6 and NMRI mice, but only partially effective in BALB/c
mice) and fully protects foetuses of vaccinated NMRI dams against
direct intra-placental ZIKV challenge. During revision of the
current study, another chimeric YFV-17D-based ZIKV vaccine
candidate (ChimeriVax-Zika, CYZ) was reported.44 The immuno-
genicity and efficacy of CYZ (partial protection against challenge
viremia) has been demonstrated in A129 (IFNAR-KO) mice. The
molecular basis of the remarkable differences in the potency of
YF-ZIKprM/E versus CYZ warrants further investigation. Reasons for
such differences may include (i) the actual choice of the prM/E
sequence (Yap 2007 vs. French Polynesian 2013 ZIKV), (ii) the
adaptive TCA mutations acquired in YF-ZIKprM/E (Fig. 1d and
Supplementary Fig. 5 and 6), or (iii) the particular replication-
enhancing mutations in the backbone of YF-ZIKprM/E [derived
from ChimeriVax-JE6 [Supplementary Fig. 4], or (iv) combinations
thereof. The particular characteristics of YF-ZIKprM/E (in terms of
efficacy and safety in the models used here) warrants further
exploration of this chimeric virus as a vaccine candidate.
METHODS
Plasmid construction
Plasmid pShuttle/YFVax is an inducible BAC and derivative from the
synthetic construct as disclosed in WO2014174078 that was constructed
using standard recombinant DNA methods. Plasmid pShuttle/ChimeriVax-
JE was designed to contain the prM/E sequence of the Japanese
encephalitis vaccine SA14–14–2 plus two additional adaptive (missense)




























































































































































































Fig. 5 Antibody titers and protection from viremia in ifnar−/−, and wild-type mice upon ZIKV challenge. a Total antibody titers 28 days post
vaccination. Ifnar−/− mice were either sham-vaccinated with 2% FBS MEM (red circles, n= 10) or vaccinated with 1 × 104 PFU of YF-ZIKprM/E
(blue squares, n= 10) in groups of 5. C57BL/6 or BALB/c mice were either sham-vaccinated (red circles, n= 10) or vaccinated in the presence
(black squares, n= 5 or 10) or absence (blue squares, n= 10) of an interferon blocking antibody, MAR1-A53. Mice were bled by submandibular
puncture 28 days post vaccination and sera were used to quantify Ab titers by end point IIFA or viremia b at days 3 and 5 post infection. Data
are presented as mean values with error bars indicating SEM. Mann–Whitney two-tailed test was used for statistical analyses. Asterisks indicate
a significant difference: *P-values < 0.05, **P-values < 0.01, ***P-values < 0.001, ****P-values < 0.0001. Dotted lines denote the limit of detection
of the assay
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additional Kas1 site at the end of the prM/E coding sequence (Fig. 1a).
Furthermore, pShuttle/ChimeriVax-JE contains silent Xho1 (mutations 3),
BstE2 (mutation 4), and Nhe1 (mutation 5) restriction sites in the YFV-17D
sequence as depicted in supplementary Fig 1A and not present in the
original ChimeriVax-JE. The capsid anchor prM/E region of the ZIKV Yap
isolate (EU545988) corresponding to the polyprotein open-reading (ORF)
nt 313–2382 was synthetized by custom gene synthesis (Integrated DNA
Technologies, Haasrode, Belgium) as three overlapping gene blocks
namely (a) ZIK-5′A or ZIK-5′B flanked with YFV or ZIKV capsid anchor at




































































































Fig. 6 Protection from vertical transmission of ZIKV in NMRI mice in an intra-placental challenge model. a Schematic presentation of study
outline. b Seroconversion (21 days post vaccination) of pregnant murine dams prior to intra-placental challenge with ZIKV. c Virus titers in fetal
brains. qRT-PCR performed on total RNA extracts from mock- or ZIKV-infected E18.5 brains harvested from either sham-treated or vaccinated
murine dams. The copy number of ZIKV was quantified and analyzed by two-sided Kruskal–Wallis test followed by Dunn post hoc comparison.
Each group represents n= 16–22 biologically independent samples as indicated on respective scatter plots. Error bars show mean ± SEM.
Levels of significance: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 for all statistics herein; ns = not significant. d Confocal images of
representative cortical sections from mouse embryonic E18.5 brains. Immunolabellings were performed for activated cleaved caspase-3
(ACC3) and ZIKV followed by counter-staining for nuclei in the green, red and blue channels, respectively. Sham= no vaccination of murine
dams; Vac= vaccination of murine dams; IPL= Intra-placental injection at embryonic day 12.5; Mock= intra-placental challenge with mock
media; ZIKV= intra-placental challenge with Zika virus (French Polynesia H/PF13, 1 × 105 TCID50). Horizontal dotted lines denote the limit of
detection (L.O.D) of the assay
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NS1 sequences of YFV at their 3′ end. Blocks were assembled by fusion PCR
using primers containing Xho1 and Kas1 restriction sites, which allowed
ligation of the amplicons directly into the pShuttle/ChimeriVax-JE. The
construction of the mCherry variants is described elsewhere (Schmid et al.,
manuscript in preparation). The resulting construct was ligated upstream
of ZIKprM/E in the YF-ZIKprM/E construct described above.
Cells
Vero E6 and BHK-21J cells used in this study were a generous gift from
Peter Bredenbeek, LUMC, NL. Cells were maintained in Minimum Essential
Medium (MEM-Rega-3, Invitrogen Life Technologies) supplemented with
10% FBS, 2 mM L-glutamine (Gibco, Belgium), 1× Anti-Anti (Streptomycin
and Amphotericin B; Gibco Life Technologies, Belgium), 1% sodium
bicarbonate (Gibco, Life Technologies, Belgium), and incubated at 37 °C,
5% CO2.
All other cell lines (see Supplementary Table 5) were maintained in the
lab in their respective media.
Virus was generated and propagated in Vero E6 cells. To generate
viruses from plasmid constructs, 5 × 105 Vero E6 cells were transfected with
2.5 µg of plasmid DNA using TransIT®-LT1 transfection reagent (Mirus Bio
LLC, Belgium) following manufacturer’s instruction. Two days post
transfection (dpt), cells were washed twice with PBS, trypsinized and
transferred to 25 cm3 flasks in a total volume of 5ml of 2% FBS medium
containing 1× Anti-Anti. This cycle was repeated three more times at day 8,
14, and 20 post transfection, each time expanding the cell substrate by
providing increasingly larger tissue culture vessels (Supplementary Table
2). Cell culture was stopped after 25 days. Intracellular replication of
chimeric viruses launched from the inducible BACs occasionally led to the
production and release of fully infectious progeny virus particles into the
tissue culture supernatant. To allow amplification of such chimeric virus as
soon as it emerges, a fraction of the supernatant of the transfected cells
was transferred to each next cell passage. Once induction of CPE was
noted, culture supernatant was harvested, centrifuged at 3000 rpm at 4 °C,
aliquoted and stored at −80 °C before further use. To prepare the virus
stocks, YF-ZIKprM/E virus derived post intracellular passaging of dividing
cells was passaged in Vero E6 cells and passages 3 (P3) and 5 (P5) were
used for further studies.
Viruses
ZIKV strains MR766,21 SL160224, and BeH81901545 were obtained from the
European Virus Archive (EVA) (EVA; http://www.european-virus-archive.
com/viruses/zika-virus-strain-mr766), Prof. Martijn van Hemert, University
of Leiden, The Netherlands and Prof. A. Merits, University of Tartu, Estonia.
YFV-17D, Stamaril® (Sanofi-Pasteur) was passaged two times on BHK-21J
cells before use.
Animals
Mice deficient in both interferon-α/β and -γ receptors (AG129; B&K
Universal, Marshall Bio resources, UK) were bred in-house at the
Experimental Animal Facilities of the University of Leuven, Leuven,
Belgium and randomly assigned for study. All experiments using mice
strictly followed the Belgian guidelines for animal experimentation and the
guidelines of the Federation of European Laboratory Animal Science
Associations. The Ethical Committee of the Animal Research Center of the
University of Leuven pre-approved all experiments (P140–2016). Through-
out the study, 6–8 weeks old animals were vaccinated intraperitoneally (i.
p.) with 1 × 102–1 × 106 PFU of YF-ZIKprM/E prior to i.p. challenge with 1 ×
103 PFU–1 × 105 PFU of heterologous MR76621 or SL160224 strain as
essentially described.21 In addition, to determine the kinetics of protection
post vaccination, mice were challenged at 0, 7, and 14 days post
vaccination. Mice were monitored daily for signs of disease and mortality.
Animals were euthanized when they showed overt signs of disease such as
paralysis of hind limb, hunch posture, ruffled fur, watery/sunken eyes, and/
or more than 20% weight loss. To determine viremia and virus
dissemination to organs post challenge, vaccinated and non-vaccinated
mice were euthanized on day 3, 5, and 14 post challenge and blood was
collected and immediately incubated on ice after terminal heart or
submandibular puncture, after which it was centrifuged at 3000 rpm for
15min and stored at −80 °C. Similarly, various organs of these animals
were harvested on dry ice with or without RNAlater (Thermo Fischer) post
perfusion with PBS and stored at −80 °C.
BALB/c mice and pups were purchased from Janvier Labs, Le Genest-
Saint-Isle, France. Pups (n= 5 per group) were intracranially inoculated
with either 10 PFU of YFV-17D or 1 × 104 PFU of YF-ZIKprM/E and
monitored for morbidity and mortality for 21 days post inoculation.
Ifnar1−/− mice were bred in-house at the KU Leuven animal facility,
while BALB/c, C57BL/6 were purchased from Janvier Labs, Le Genest-Saint-
Isle, France. Mice were vaccinated and treated as described above for
AG129. Because immune competent mice do not readily replicate ZIKV,46
they were immunized in the presence or absence of 2 mg of an interferon
blocking antibody, MAR1-5A3, administered i.p. 1 day prior to immuniza-
tion. Twenty-one days post immunization, mice were bled by submandib-
ular puncture and scored for the presence of antibodies in sera prior to i.p.
challenge with 1 × 104 PFU ZIKV MR766. Vaccinated and sham-vaccinated
BALB/c and C57BL/6 mice were injected i.p. with 2 mg of MAR1-5A3 to
render them susceptible to infection.46 Mice were bled on days 3 and 5
post challenge for RNA quantification by qRT-PCR.
Immunocompetent NMRI wild-type female mice (adult at 2–3 months of
age) were purchased from Janvier Laboratories, France and treated as
approved by the Animal Ethics Committee of the University of Liège (#16-
1829). Timed-mated dams were housed in specific-pathogen-free facility
under standard conditions, with ad libitum access to food and water. One
day prior to i.p vaccination with either 1 × 104 PFU YF-ZIKprM/E or 2% FBS
MEM (mock), mice were administered 2mg of MAR1-5A3. Fourteen (14)
days post vaccination, mice were mated with NMRI males and mating
plugs were observed the following day, embryonic day 0.5 (E0.5). At E12.5,
pregnant females were operated upon (mini-laparotomy) and challenged
intra-placentally (IPL) with 1 × 105 TCID50 of ZIKV strain H/PF13. Incisions
were sutured, and mice were observed for 6 days (E18.5) and euthanized
thereafter to determine fetal infection and malformations. The intra-
placental injections of embryos at E12.5 were performed as previously
described28 with slight modifications. Surgeries were performed at noon,
when the day after mating was considered E0.5. Pre-operative analgesia
with Temgesic (buprenorphine 0.1 mg/kg body weight, Schering-Plough,
Brussels, Belgium) was administered subcutaneously before induction of
anesthesia with isoflurane (Abbot Laboratories Ltd, Kent, UK) in an oxygen
carrier. Subsequently, a mini-laparotomy (1.0 to 1.5 cm incision) was
performed through the lower ventral peritoneum. The uterine horns were
carefully extracted and placed on warm humidified gauze pads.
Virus growth kinetics
To assess the growth kinetics of YF-ZIKprM/E and YFV-17D on Vero E6 and
mosquito cells (C6/36), cells were seeded over night at a density of 1 × 106
cells per well of a 6-well plate in a total volume of 3ml 10% FBS MEM or
Leibovitz’s L-15 medium (supplemented with 10% FBS, 1% Penicillin/
Streptomycin, tryptose phosphate broth, and nonessential amino acids),
respectively. Vero E6 and C6/36 cells were washed twice with PBS prior to
infection with 1 × 104 PFU of either YFV-17D or YF-ZIKprM/E (MOI= 0.01)
and incubated at 37 or 28 °C, respectively, for 1 h. Cells were again washed
twice and 3ml of either 2% FBS MEM or Leibovitz’s L-15 medium,
respectively, was added and plates were incubated at appropriate
temperatures. Overall, 250 µl of supernatants were harvested daily (and
replaced with 250 µl fresh medium) for RNA extraction and quantification.
All experiments were done in duplicate and data presented as mean ± SEM.
RNA extraction and qRT-PCR
RNA extractions from serum and organs fixed in RNAlater were performed
as described elsewhere.21
Quantification of Zika virus copy number in infected fetal mouse brains
was done by qRT-PCR and calculated according to previously published
protocol.28 Briefly, a standard curve was created by performing serial
dilutions of the plasmid containing a 76-bp long sequence (inserted
BamH1/Xho1) from the Zika genome (from nt 1086 to 1162) and querying
these dilutions by qRT-PCR analysis. The following primers were used to
create the standard curve: ZIKV 1,086 (genome pos. 1,086–1,102): 5′-
CCGCTGCCCAACACAAG-3′; ZIKV: 1,162c (genome pos. 1,162–1,139): 5′-
CCACTAACGTTCTTTTGCAGACAT-3′. The standard curve allows conversion
of the Cp of samples into no. of Zika copies/μl. The following formula as
previously described was used:
Number No:ð Þ of copies=μl ´ k ´ d ´ P ¼ No: of copies=μg RNA
where k is a correction factor introduced to calculate the no. of copies with
respect to 1 μg of RNA (in this instance 0.5 μg of RNA was used to synthetize
cDNA, so k= 2), d is a dilution factor, taking into account the dilution of cDNA
used for the analysis (in this case the cDNA was diluted 1:30, so d= 30) and P is
a correction factor introduced to calculate the no. of Zika copies with respect
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to the total amount of cDNA (here 3.4 μl in a total of 20μl of cDNA mix were
used, so P= 5.88). Finally, the no. of copies/μg RNA was divided for the relative
concentration of each sample analyzed by qRT-PCR.
Immunohistochemistry
Embryonic (E) E18.5 mouse brains were dissected in 0.1 M phosphate-
buffered saline pH 7.4 (PBS) and fixed in 4% paraformaldehyde (PFA in
PBS) for 1 h at room temperature (20 to 24 °C), followed by cryoprotection
(30% sucrose in PBS) before embedding in gelatin for cryosectioning at
14 μm (Leica) onto slides (SuperFrost Plus, VWR International).
Fluorescent immunohistochemistry was performed as previously
described.28 In summary, antigen retrieval (Dako Target Retrieval Solution)
of mouse brains were performed at 95 °C for 15min before incubation with
primary antibodies. The following primary antibodies were used anti-
cleaved-caspase-3 (1:100, rabbit, #9661, CST); anti-flavivirus group antigen
(1:1000, mouse, MAB10216, Millipore). The respective secondary antibodies
used were anti-mouse, and anti-rabbit antibodies, conjugated with Alexa
Fluor-488 or Alexa Fluor-555 (Jackson ImmunoResearch Laboratories or
Life Technologies) and diluted at 1:800.
Nuclei were counter-stained with DAPI (1:10,000, Sigma) and mounted
in Mowiol (Sigma) solution.
Plaque assay and plaque reduction neutralization test (PRNT)
Infectious virus titers in serum and organs were also determined by plaque
assay. In brief, 1 × 106 BHK-21J cells per well of a 6-well plate were seeded
overnight in seeding medium, washed twice in PBS and incubated with
serial dilutions of virus in assay medium for 1 h at 37 °C. Later, virus was
removed, cells were again washed twice with PBS and overlaid with 0.5%
low melting agarose (Invitrogen) prepared in overlay medium (MEM plus
2% FBS). Agar was allowed to solidify at room temperature prior to
incubation at 37 °C for 7 days. Thereafter, cells were fixed with 4%
formaldehyde and plaques were visualized by staining with 1% crystal
violet for 5 min. Plaques were manually counted and reported as PFU/ml of
virus stock. Virus neutralizing antibodies (nAb) are defined operationally by
their ability to prevent virus infection in tissue culture and/or in vivo
infection models. The presence of ZIKV-specific nAb was determined
quantitatively by plaque reduction neutralization test (PRNT). For PRNT,
40–80 PFU of ZIKV MR766 were incubated for 1 h with a dilution series of
sera prior to addition to BHK-21J cells as described above. For each
immune serum a median PRNT (PRNT50) titer [determined in technical
triplicates and expressed as geometric mean thereof] was defined as
dilution at which the plaques count was reduced to less than 50% of the
mean number of plaques from untreated virus inocula (obtained by back
titration of inocula in the same experiment).
Immunofluorescence assay (IFA)
Virus replication and spread was monitored using an in-house developed
IFA. To achieve this, 300 µl of transfected cell suspension derived after
trypsinization and resuspension in appropriate volume of MEM plus 2%FBS
was transferred to wells in an 8-well Lab-Tek chamber slide (ThermoFisher
Scientific, USA) and stained at indicated time points. Briefly, cells were
washed twice with PBS, fixed with 4% paraformaldehyde for 20min
followed by two washes and permeabilization with 0.1% Triton X-100 for
5 min. Cells were again washed twice with PBS and covered with blocking
buffer (1% FBS in PBS and 0.05% Tween-20). After 1 h of incubation at
room temperature, blocking buffer was removed and 200 µl of pan-
flavivirus mouse monoclonal antibody 4G2 (1:1000, mouse, MAB10216,
Millipore) diluted in blocking buffer was added and the slide was rocked
on a shaker at 300 rpm for 1 h. Cells were washed 3 times (5 min per wash
on a shaker) with wash buffer (PBS+ 0.05% Tween-20) and counter-
stained with goat anti-mouse secondary antibody conjugated with a
fluorescent probe, Alexa 488 (1:1000, goat anti-mouse, A11001, Life
Technologies, USA). Secondary antibody was removed and the cells were
again washed 3 times (5min per wash on shaker) with wash buffer. Finally,
cells were covered with a mounting medium that contained a DAPI stain
for nuclear staining (blue) and observed under a fluorescent microscope
(Floid Cell Imaging Station, ThermoFisher, Germany).
To detect ZIKV-specific antibodies in mouse serum, indirect IFA (IIFA)
was used as described above with some modifications. Briefly, Vero E6 cells
were infected with the ZIKV BeH819015;45 M.O.I 0.01 and incubated for
3 days to allow > 95% infection of cells. Cells were then washed,
trypsinized, and resuspended in 2% FBS medium. Three hundred (300)
µl of cell suspension was transferred to 8-well Lab-Tek chamber slides and
incubated for 6 h or overnight prior to the experiment. The infected cells
served as antigen for the detection of antibodies in sera of vaccinated
mice. To determine seroconversion, antibody titrations were performed
starting from 1:10 to 1:128,000 from which 100 µl was added to ZIKV-
infected cells in a 96-well plate. All downstream steps were performed as
described above for IFA.
Antigens for T cell assays
For in vitro stimulation, a ZIKV E peptide pool (JPT Peptide Technologies
GmbH, Berlin, Germany) and an MHC I Haplotype class-restricted YFV-17D
NS3 peptide47 (sequence ATLTYRML, Eurogentec, Seraing, Belgium) were
used. For the production of cell lysates, Vero E6 cells were infected with
YFV-17D (Stamaril®, SanofiPasteur) or Zika virus (BeH819015). Two days
after infection, cells were subjected to serial freeze-thaw cycles, inactivated
by 254 nm UV irradiation overnight and the diluted cell lysate (50 µg/ml)
was used as antigen for the stimulation of splenocytes. Non-infected Vero
E6 cell lysate was used as a negative control.
Intracellular cytokine staining and flow cytometry
Fresh mouse splenocytes were plated in a 96 round-bottom well plate
(Costar, Corning Inc., Corning, NY, USA) at a density of 2 × 106 cells/well
and incubated overnight with either 1 µM/peptide of the ZIKV E peptide
pool, or 5 µM of YFV-17D NS3 ATLTYRML or 50 µg/ml of Vero E6 cell lysate.
After treatment with 5 µg/ml brefeldin A (Biolegend, San Diego, CA, USA)
for 2 h, the splenocytes were stained for viability with Zombie Aqua™
(Biolegend) (1:200 dilution in PBS) for 15min. Subsequently, extracellular
markers CD3 (4 µg/ml eFluor® 450 anti-mouse CD3 antibody, Thermo-
Fisher, Waltham, MA, USA) and CD8 (2 µg/ml APC/Cy7 anti-mouse CD8a
antibody, Biolegend) were stained and cells were fixed in 2% paraformal-
dehyde (Sigma-Aldrich, St. Louis, MO, USA). Finally, splenocytes were
permeabilized with 0.1% saponin before intracellular staining for IFN-γ
(2 µg/ml APC anti-mouse IFN-γ, Biolegend), TNF-α (6.5 µg/ml PE anti-mouse
TNF-α, Biolegend) and granzyme B (5 µg/ml FITC anti-human/mouse
granzyme B, Biolegend). Samples were analyzed on a BD LSRFortessa™ X-
20 (Becton Dickinson, Franklin Lakes, NJ, USA). Percentages of responding
CD4+ or CD8+ T cells were calculated by subtracting the percentage of
responders from non-stimulated samples (incubated with non-infected
Vero E6 cell lysates) from corresponding stimulated samples.
ELISPOT
An ELISPOT assay for the detection of IFN-γ-secreting mouse splenocytes was
performed with a mouse IFN-γ ELISPOT kit (ImmunoSpotMIFNG-1M/5, CTL
Europe GmbH, Bonn, Germany). Per well, 4 × 105 mouse splenocytes were
incubated with antigen (1 µM/peptide of the ZIKV E peptide pool, 5 µM of the
YFV-17D NS3 ATLTYRML peptide, or 50 µg/ml of the Vero E6 cell lysates) at
37 °C for 24 h. One day after, IFN-γ spots were visualized by stepwise addition
of a biotinylated detection antibody, a streptavidin-enzyme conjugate and the
substrate. Spots were counted using an ImmunoSpot S6 Universal Reader (CTL
Europe GmbH) and normalized by subtracting the number of spots from
samples incubated with non-infected Vero E6 cell lysates from the spot
number of corresponding stimulated samples.
Measurement of pro-inflammatory cytokines and chemokines
Induction of pro-inflammatory cytokines and chemokines was analyzed in
20 μl serum using the mouse cytokine 20-plex antibody bead kit
(ProcartaPlex Mouse Th1/Th2 & Chemokine Panel I [EPX200-26090-901]).
Measurements of the expression of TNF-α, IFN-γ, IL-6, IL-18, CCL2 (MCP-1),
CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL7 (MCP-3), CCL11
(Eotaxin), CXCL1 (GRO-α), CXCL2 (MIP-2), CXCL10 (IP-10), GM-CSF, IL-1β,
IL12p70, IL-13, IL-2, IL-4, and IL-5. Measurements were performed using a
Luminex 100 instrument (Luminex Corp., Austin, TX, USA) and were
analyzed using a standard curve for each molecule (ProcartaPlex). Data are
displayed as median values. Statistical analysis was performed using a
Mann–Whitney two-tailed test
Statistical analysis
Data were analyzed using GraphPad Prism v7 software and expressed as
mean values ± standard error of mean (SEM). Comparison of groups was
performed using either one-way ANOVA or Mann–Whitney two-tailed test,
with P values < 0.05 indicating a statistically significant difference between
groups.
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For vertical transmission studies and fetal RNA quantifications, GraphPad
Prism software (version 6.02) was used for the analyses, where statistical
tests were applied according to the distribution, variance, normality of
each dataset as well as the number of biological replicates in each
experiment as specified in the figure legends. The Iglewicz and Hoaglin’s
Test was applied to exclude outliers, where the modified Z-score was set to
3.5. Kolmogorov–Smirnov test was used to determine distribution of
dataset and normality. Multiple comparisons were performed with
Kruskal–Wallis followed by Dunn’s post hoc tests for nonparametric
datasets.
Levels of significance: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05
for all statistics herein; ns = not significant.
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